Biocardia enters agreement with bluerock therapeutics to provide enabling catheter biotherapeutic delivery product candidates for bluerock's cell therapy to treat heart failure

Sunnyvale, calif., aug. 24, 2022 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], today announced that it has entered into an agreement with bluerock therapeutics lp for the delivery of bluerock's cell therapy product candidates for the treatment of heart failure utilizing biocardia's minimally invasive biotherapeutic delivery product candidates.
BCDA Ratings Summary
BCDA Quant Ranking